1nq9: Difference between revisions
No edit summary |
No edit summary |
||
| Line 4: | Line 4: | ||
|PDB= 1nq9 |SIZE=350|CAPTION= <scene name='initialview01'>1nq9</scene>, resolution 2.60Å | |PDB= 1nq9 |SIZE=350|CAPTION= <scene name='initialview01'>1nq9</scene>, resolution 2.60Å | ||
|SITE= | |SITE= | ||
|LIGAND= <scene name='pdbligand=NAG:N-ACETYL-D-GLUCOSAMINE'>NAG</scene> | |LIGAND= <scene name='pdbligand=NAG:N-ACETYL-D-GLUCOSAMINE'>NAG</scene>, <scene name='pdbligand=NTP:HEPARIN+PENTASACCHARIDE'>NTP</scene> | ||
|ACTIVITY= | |ACTIVITY= | ||
|GENE= | |GENE= | ||
|DOMAIN= | |||
|RELATEDENTRY=[[1e03|1E03]], [[1e05|1E05]], [[1e04|1E04]], [[1oyh|1OYH]] | |||
|RESOURCES=<span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=1nq9 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=1nq9 OCA], [http://www.ebi.ac.uk/pdbsum/1nq9 PDBsum], [http://www.rcsb.org/pdb/explore.do?structureId=1nq9 RCSB]</span> | |||
}} | }} | ||
| Line 24: | Line 27: | ||
[[Category: Huntington, J A.]] | [[Category: Huntington, J A.]] | ||
[[Category: Johnson, D J.D.]] | [[Category: Johnson, D J.D.]] | ||
[[Category: | [[Category: heparin analogue]] | ||
[[Category: | [[Category: inhibition]] | ||
[[Category: | [[Category: serine protease inhibitor]] | ||
[[Category: thrombin]] | |||
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on | ''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Sun Mar 30 22:34:01 2008'' | ||
Revision as of 22:34, 30 March 2008
| |||||||
| , resolution 2.60Å | |||||||
|---|---|---|---|---|---|---|---|
| Ligands: | , | ||||||
| Related: | 1E03, 1E05, 1E04, 1OYH
| ||||||
| Resources: | FirstGlance, OCA, PDBsum, RCSB | ||||||
| Coordinates: | save as pdb, mmCIF, xml | ||||||
Crystal Structure of Antithrombin in the Pentasaccharide-Bound Intermediate State
OverviewOverview
Antithrombin is activated as an inhibitor of the coagulation proteases through its specific interaction with a heparin pentasaccharide. The binding of heparin induces a global conformational change in antithrombin which results in the freeing of its reactive center loop for interaction with target proteases and a 1000-fold increase in heparin affinity. The allosteric mechanism by which the properties of antithrombin are altered by its interactions with the specific pentasaccharide sequence of heparin is of great interest to the medical and protein biochemistry communities. Heparin binding has previously been characterized as a two-step, three-state mechanism where, after an initial weak interaction, antithrombin undergoes a conformational change to its high-affinity state. Although the native and heparin-activated states have been determined through protein crystallography, the number and magnitude of conformational changes render problematic the task of determining which account for the improved heparin affinity and how the heparin binding region is linked to the expulsion of the reactive center loop. Here we present the structure of an intermediate pentasaccharide-bound conformation of antithrombin which has undergone all of the conformational changes associated with activation except loop expulsion and helix D elongation. We conclude that the basis of the high-affinity state is not improved interaction with the pentasaccharide but a lowering of the global free energy due to conformational changes elsewhere in antithrombin. We suggest a mechanism in which the role of helix D elongation is to lock antithrombin in the five-stranded fully activated conformation.
About this StructureAbout this Structure
1NQ9 is a Single protein structure of sequence from Homo sapiens. Full crystallographic information is available from OCA.
ReferenceReference
Crystal structure of antithrombin in a heparin-bound intermediate state., Johnson DJ, Huntington JA, Biochemistry. 2003 Jul 29;42(29):8712-9. PMID:12873131
Page seeded by OCA on Sun Mar 30 22:34:01 2008